An initial project proposal, of no more than one or two pages, can be submitted to Catalyst Therapeutics.Musam haribus aut et, solorum et quatisc iendem solupta spedit rem aut dolendem resequi duciusti dolorate estrumquam qui isi tem quam litatestis aut autesed quo
quaturem dolupti non nobit, tem in expelis totasitas ullorro tem quam suntiorem quam rem aut et qui bea voluptatur?

Open to opportunities

Catalyst Therapeutics is open to opportunities from the following:

- Walter and Eliza Hall Institute 
- Walter and Eliza Hall Institute collaborators
- External parties, where there is a strategic alignment with the interests of the Walter and Eliza Hall Institute and/or SYNthesis Research

A critical determinant will be links to biological and clinical contributions and an ability to contribute to the Walter and Eliza Hall Institute’s core vision.

Project proposals are submitted to the Catalyst Therapeutics portfolio advisory group.

Once a project is selected for development, the portfolio manager will develop a tailored project plan and draw upon the resources of both the Walter and Eliza Hall Institute and SYNthesis Research to build a project team to take the project to the late lead/clinical candidate stage.

Through engagement with Catalyst Therapeutics, benefits include:

- Value creation
- Shared risk
- Opportunity to engage new investment sources
- Access to the Australian R&D Tax Incentive
- Potential access to MRCF and BTF funds, worth a combined AUD 700 million
- Access to an international network

 

An initial project proposal, of no more than one or two pages, can be submitted to Catalyst Therapeutics.